Загрузка...
Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)
Respiratory syncytial virus (RSV) is a leading cause of hospitalization in children less than 1 year of age and causes substantial morbidity. Although there is not currently a vaccine available to prevent RSV infection, prophylaxis with the humanized monoclonal antibody palivizumab has been shown to...
Сохранить в:
| Главные авторы: | , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2007
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2721348/ https://ncbi.nlm.nih.gov/pubmed/19707346 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|